Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10907479 | PMC |
| http://dx.doi.org/10.1007/s00417-023-06358-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases.
Graefes Arch Clin Exp Ophthalmol
December 2024
Doheny Eye Institute, University of California, Los Angeles, 150 N. Orange Grove Blvd, Suite 232, Pasadena, CA, USA.
Anti-vascular endothelial growth factor (VEGF) therapies have transformed the treatment of retinal diseases. However, VEGF signaling is only one component of the complex, multifactorial pathophysiology of retinal diseases, and many patients have residual disease activity despite ongoing anti-VEGF treatment. The angiopoietin/tyrosine kinase with immunoglobulin and epidermal growth factor receptor-2 (Ang/Tie2) signaling pathway is critical to endothelial cell homeostasis, survival, integrity, and vascular stability.
View Article and Find Full Text PDFGraefe's Archive for Clinical and Experimental Ophthalmology-170th anniversary interview with editor-in Chief-Vas Sadda.
Graefes Arch Clin Exp Ophthalmol
December 2024
Di-Ep Biomedical Editorial Services Ltd, Editorial Office, Graefes Archive for Clinical and Experimental Ophthalmology, Glasgow, UK.
170th anniversary of Graefe's Archive for Clinical and Experimental Ophthalmology.
Graefes Arch Clin Exp Ophthalmol
October 2024
Eye Hospital, Research Area "History of Ophthalmology", Eberhard-Karls-University, Tübingen, Germany.
The year 2024 marks the 170th anniversary of the journal Graefe's Archive for Clinical and Experimental Ophthalmology. The journal is the first printed journal specializing in ophthalmology, founded by Albrecht von Graefe (1828-1870) in 1854. The reason behind creating the journal was to publish useful clinical information and develop discussion and debate among ophthalmologists and vision scientists.
View Article and Find Full Text PDFAnti-VEGF therapy for the long-term management of diabetic macular edema: a treat-to-target strategy based on macular morphology.
Graefes Arch Clin Exp Ophthalmol
December 2024
Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
In an aging population, the prevalence and burden of diabetes mellitus, diabetic retinopathy, and vision-threatening diabetic macular edema (DME) are only expected to rise around the world. Similarly to other complications of diabetes mellitus, DME requires long-term management. This article aims to review the current challenges associated with the long-term management of DME, opportunities to improve outcomes for patients, and to develop a treat-to-target strategy based on macular morphology.
View Article and Find Full Text PDFBackground: We aimed to update estimates of global vision loss due to age-related macular degeneration (AMD).
Methods: We did a systematic review and meta-analysis of population-based surveys of eye diseases from January, 1980, to October, 2018. We fitted hierarchical models to estimate the prevalence of moderate and severe vision impairment (MSVI; presenting visual acuity from <6/18 to 3/60) and blindness ( < 3/60) caused by AMD, stratified by age, region, and year.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!